tbuckley/cabot-search huggingface dataset:
The Promotion of Gabapentin
Authors: Thomas E. Finucane
Journal: Annals of Internal Medicine (2007)

Letters20 February 2007The Promotion of GabapentinThomas E. Finucane, MDThomas E. Finucane, MDFrom Johns Hopkins Bayview Medical Center, Baltimore, Maryland.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-146-4-200702200-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR: Steinman and colleagues (1) describe an explicit promotional campaign by gabapentin's vendor that included efforts to inflate the literature on the drug “by contracting with medical education companies to develop review papers, original articles, and letters to the editor” that were favorable to gabapentin and then hiring physicians and pharmacists to be authors on these papers. Knowing that this was done makes the literature on gabapentin very difficult to interpret.A PubMed search (performed on 25 August 2006) of gabapentin limited to randomized, controlled trials found 148 trials. Primary research literature includes several positive trials of gabapentin ...Reference1. Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006;145:284-93. [PMID: 16908919] LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Thomas E. Finucane, MDAffiliations: From Johns Hopkins Bayview Medical Center, Baltimore, Maryland.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoNarrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents Michael A. Steinman , Lisa A. Bero , Mary-Margaret Chren , and C. Seth Landefeld The Promotion of Gabapentin Eric D. Peterson , Kurt Boyce , and Karen Overstreet The Promotion of Gabapentin Benjamin L. Sapers The Promotion of Gabapentin Michael A. Steinman , Mary-Margaret Chren , C. Seth Landefeld , and Lisa A. Bero Metrics 20 February 2007Volume 146, Issue 4Page: 312-313KeywordsAlcoholsBipolar disorderClinical trialsConflicts of interestDrugsHeadachesMedical educationNystagmusPharmacistsRestless legs syndrome ePublished: 20 February 2007 Issue Published: 20 February 2007 Copyright & PermissionsCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
RARRES2, encoding the novel adipokine chemerin, is a genetic determinant of disproportionate regional body fat distribution: a comparative magnetic resonance imaging study
Authors: Karsten Müssig, Harald Staiger, Fausto Machicao, Claus Thamer, Jürgen Machann, Fritz Schick, Claus D. Claussen, Norbert Stefan, Andreas Fritsche, Hans-Ulrich Häring
Journal: Metabolism (2009)
Euglycemic diabetic ketoacidosis.
Authors: J T Ireland, W S Thomson
Journal: BMJ (1973)

the consultant should have the final say over who gets his job, but I feel he has a duty, having agreed to participate in the matching plan, to see all the students interested in his job before making his choice.If the number of oonsultants breaking the rules like this were to increase, then the whole scheme would break down.Obviously there are advantages of the scheme which make it preferable to the previous state of affairs, such as the rules about no student holding more than one teaching hospital post and all jobs starting on standardized dates.However, the de- ficiencies mentioned above, must, I feel, be corrected if it is to be fair.-Iamn, etc.,
Mechanisms of Enhanced β-Adrenergic Reserve From Cardiac Resynchronization Therapy
Authors: Khalid Chakir, Samantapudi K. Daya, Takeshi Aiba, Richard S. Tunin, Veronica L. Dimaano, Theodore P. Abraham, Kathryn Jaques, Edwin W. Lai, Karel Pacak, Wei-Zhong Zhu, Rui-ping Xiao, Gordon F. Tomaselli, David A. Kass
Journal: Circulation (2009)

Cardiac resynchronization therapy (CRT) is the first clinical heart failure treatment that improves chamber systolic function in both the short-term and long-term yet also reduces mortality. The mechanical impact of CRT is immediate and well documented, yet its long-term influences on myocyte function and adrenergic modulation that may contribute to its sustained benefits are largely unknown.We used a canine model of dyssynchronous heart failure (DHF; left bundle ablation, atrial tachypacing for 6 weeks) and CRT (DHF for 3 weeks, biventricular tachypacing for subsequent 3 weeks), contrasting both to nonfailing controls. CRT restored contractile synchrony and improved systolic function compared with DHF. Myocyte sarcomere shortening and calcium transients were markedly depressed at rest and after isoproterenol stimulation in DHF (both anterior and lateral walls), and CRT substantially improved both. In addition, beta(1) and beta(2) stimulation was enhanced, coupled to increased beta(1) receptor abundance but no change in binding affinity. CRT also augmented adenylate cyclase activity over DHF. Inhibitory G-protein (Galpha(i)) suppression of beta-adrenergic stimulation was greater in DHF and reversed by CRT. Galpha(i) expression itself was unaltered; however, expression of negative regulators of Galpha(i) signaling (particularly RGS3) rose uniquely with CRT over DHF and controls. CRT blunted elevated myocardial catecholamines in DHF, restoring levels toward control.CRT improves rest and beta-adrenergic-stimulated myocyte function and calcium handling, upregulating beta(1) receptors and adenylate cyclase activity and suppressing G(i)-coupled signaling associated with novel RGS upregulation. The result is greater rest and sympathetic reserve despite reduced myocardial neurostimulation as components underlying its net benefit.
Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint
Authors: E Archimbaud, C Charrin, J-P Magaud, L Campos, X Thomas, D Fière, R Rimokh
Journal: Leukemia (1998)
Statins may reduce risk of Alzheimers disease
Authors: D. Josefson
Journal: BMJ (2000)

Patients taking the statin class of cholesterol lowering drugs may derive the extra benefit of a reduction in risk of Alzheimer's disease, according to a new study ( Archives of Neurology 2000;57:1439-43).

As high levels of cholesterol have been associated with Alzheimer's disease, and a cholesterol transport isoprotein, apolipoprotein E4, is known to increase the risk of the disease, the study authors set out to determine if statins could reduce the incidence of Alzheimer's disease.

Led by Dr Benjamin Wolozin of Loyola University Medical Center in Maywood, Illinois, and Paul Rousseau of the Carl T Hayden Veteran …
Liver Biology and Pathobiology
Authors: Neil Kaplowitz
Journal: Hepatology (2006)

During the past 4 years, many interesting and important advances in liver biology and pathobiology have been identified in the Highlights section. However, several recurrent themes stand out reflecting foci of research for which HEPATOLOGY has provided a major forum in rapidly advancing fields. These include apoptosis, drug-induced liver injury, and alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD). Some of the previously highlighted articles in these three areas of research will be put in the context of these rapidly evolving fields.
Editorial: HL-A system and rheumatic diseases
Authors: Z. Danilevicius
Journal: JAMA (1975)

Since the first leukocyte antigen group was described in 1958 by Dausett,<sup>1</sup>the HL-A system became the major tool in the studies of human histocompatibility. It gained great importance in human organ transplantation, in prevention of transplant rejection, and in the fight against the host vs graft reaction. The HL-A system had its beginning in the detection in the serum of polytransfused patients of antibodies capable of agglutinating leukocytes, which were independent of blood group antibodies, and with a second observation that such antigens were L antigens distributed in group fashion in the population. Today, with the expansion of HL-A system studies, the emphasis began shifting into other areas of medical science. An increasing number of diseases have been shown to be associated with the HL-A system. Various manifestations of the hay fever-allergy syndrome are inherited in families with HL-A chromosomes. Illnesses with immunological components, such as myasthenia gravis
Joining Forces: A Call for Greater Collaboration to Study New Medicines in Children and Adolescents With Type 2 Diabetes
Authors: Janina Karres, Valerie Pratt, Jean-Marc Guettier, Jean Temeck, William V. Tamborlane, David Dunger, Cristina Bejnariu, Carine De Beaufort, Paolo Tomasi
Journal: Diabetes Care (2014)

The number of individuals with type 2 diabetes (T2D) is increasing worldwide and is projected to rise further over the next decades (1). The prevalence of T2D diabetes in the pediatric population is also rising and in the U.S. one in three new cases of diabetes mellitus diagnosed in patients younger than 18 years of age is T2D (2,3). In contrast, the prevalence of T2D in the European pediatric population remains relatively low (4–7).

Diabetes complications in children and adolescents may be evident as early as 2 years after diagnosis (8). Data from the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study suggest almost half of children and adolescents with T2D in the U.S. have suboptimal glycemic control after 4–5 years of treatment with metformin monotherapy (9) and that hypertension, dyslipidemia, and early microvascular complications (e.g., nephropathy and retinopathy) are highly prevalent in these patients (10–12). There is therefore a need to make additional safe and effective treatment options available to youths with T2D.

Therapeutic options to treat pediatric T2D in the U.S. are limited, as only 2 of the 12 classes of glucose-lowering agents with an approved adult T2D indication have a pediatric indication. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) enforce legislation that requires pharmaceutical companies to define how they will establish the safety and efficacy of new therapeutic products for use in children and adolescents, age less than 18 years (13–15). Under current U.S. and European (EU) laws, new therapeutic products with the potential to benefit children are required to be studied unless a waiver is granted.

Although FDA and EMA pediatric processes differ, pharmaceutical companies use a single pediatric …
The Winds of Helvetia
Authors: Hans Zollikofer
Journal: JAMA (1974)

<h3>To the Editor.—</h3> Obviously, Drs. de Takats and Cohan should spend more time in Switzerland in order to get acquainted with the<i>Föhn</i>problems (228:287 and 288, 1974). During this meteorological condition, there is not only an increase in the admissions to mental hospitals, particularly due to suicidal attempts, but also to surgical and medical wards. There also is an increase in such events as accident-proneness and myocardial infarction. Furthermore, a distinct increase in hospital mortality, above all by thromboembolic complications, has been described. However, the<i>Föhn</i>is not just a wind. It is not felt blowing in the larger agglomerations such as Zurich, where most of the aforementioned studies have been performed. Neither has it much to do with electric potentials, which are known to play a role in the sensitiveness to changes of weather. The<i>Föhn</i>is mostly a warm wind coming from the south which, after crossing
Quality care at the end of life
Authors: P. A Singer
Journal: BMJ (2002)

Worldwide, 56 million people die each year, 85% of these in developing countries. 1 2 Yet little is known about the quality of care they receive at the end of their lives. The movement for improving the quality of care at the end of life is primarily focused on industrialised countries. Until it is seen as a global problem for public health and health systems, efforts to improve it will not make much impact in the world.

Quality of care at the end of life is a global public health problem because of the large number of people involved. If each death affects five other people in terms of giving informal care and grieving relatives and friends, the total number of people affected each year by end of life care is about 300 million, or 5% of the world's population.

Some of the interventions that could be used to improve care are in the realm of public health. These include large scale, culturally specific, educational programmes for public health workers and the public; population based strategies to destigmatise death and put it into the mainstream of health systems; and changes in social policies in relation to care for orphans.

Improving care at the end of life will require research in public health. Of the many papers …
Influenza A and C in Glasgow, 1954
Authors: N. R. Grist
Journal: BMJ (1955)

INFLUENZA VIRUS Cbetween 35 and 44 years is worth noting, though it may well have been due to chance.It seems reasonable to conclude that a high proportion-probably the majority of persons in this country-have encountered the virus at some time during childhood or early adult life.Our results give no indication of the extent to which infection was accom- panied by illness nor the part played by reinfection in the maintenance of antibody levels.The fact that 8 of the 10 cases reported here were drawn from 7 out of 25 families observed for only 18 months suggests that infection with influenza virus C is not uncommon.
Clinicopathological forms and prognostic index in Budd-Chiari syndrome
Authors: Philippe Langlet, Sylvie Escolano, Dominique Valla, Delphine Coste-Zeitoun, Cecile Denie, Alain Mallet, Victor-Georges Levy, Dominique Franco, Jean-Pierre Vinel, Jacques Belghiti, Didier Lebrec, Jean-Marie Hay, Guy Zeitoun
Journal: Journal of Hepatology (2003)
Heart surgery halted because of staff exhaustion
Authors: Roger Dobson
Journal: BMJ (2004)

Elective heart surgery at a Welsh hospital was recently been halted for a week to allow staff to recover after excessive workloads.

“The cardiac operating team at Morriston Hospital has been working under considerable pressure, involving staff working overtime and additional hours. To allow staff to recover from these pressures it has been decided to limit activity to emergencies only for the next week,” said Andrew …
Secretory component as the receptor for polymeric IgA on rat hepatocytes.
Authors: E Orlans, J Peppard, J F Fry, R H Hinton, B M Mullock
Journal: The Journal of Experimental Medicine (1979)

Rat hepatocytes in short-term monolayer cultures bound radiolabeled polymeric rat IgA but not IgG. The binding of 125I-IgA was inhibited equally well by unlabeled polymeric IgA and by antiserum to rat secretory component (SC). The antibody to SC, after specific purification and radiolabeling, was bound to hepatocytes as effectively as the IgA. These results indicate that SC acts as the receptor for polymeric IgA on rat hepatocytes as it does on human gut epithelia, and that the transport of IgA from blood to bile in rats across the liver is analogous to that of IgA across human enterocytes.
Finding the Missing Link for Big Biomedical Data
Authors: Griffin M. Weber, Kenneth D. Mandl, Isaac S. Kohane
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mechanism of Chlorpropamide Action in Diabetes Insipidus.
Authors: Myron Miller
Journal: Annals of Internal Medicine (1970)

Meeting Abstracts1 May 1970Mechanism of Chlorpropamide Action in Diabetes Insipidus.Myron Miller, M.D., F.A.C.P., Arnold M. Moses, M.D., F.A.C.P.Myron Miller, M.D., F.A.C.P., Arnold M. Moses, M.D., F.A.C.P.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-72-5-789_4 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptChlorpropamide has been shown to produce an antidiuresis when administered to patients with antidiuretic hormone (ADH)-sensitive diabetes insipidus (DI). The mechanism by which the drug acts has been studied both in patients with DI and in rats with hereditary hypothalamic DI and with a complete deficiency of ADH. Fourteen patients with various degrees of severity of DI and nine normal water loaded subjects were studied under metabolic conditions on a fixed sodium and potassium intake. By means of a dehydration test, 11 of the patients were shown to have some degree of residual ADH function while 3 patients were considered... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Syracuse, N.Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1970Volume 72, Issue 5Page: 789-790KeywordsAntidiuretic hormoneDrugsPotassiumSodium Issue Published: 1 May 1970 PDF downloadLoading ...
Seasonal Trends in US Asthma Hospitalizations and Mortality
Authors: Kevin B. Weiss
Journal: JAMA (1990)

Asthma morbidity is known to exhibit seasonal periodicity. Yet the relationship between trends in morbidity vs mortality is not known. This report describes and compares the seasonal variation in asthma hospitalizations and mortality in the US population. During 1982 through 1986, both mortality and hospitalizations demonstrated periodic seasonal trends that were age specific and did not differ by sex, race, or region. For persons aged 5 through 34 years, hospitalizations peaked in September through November, whereas mortality trends peaked in June through August. A disproportionate number of the summer deaths in this age group occurred out of the hospital. For individuals 65 years old or older, both asthma hospitalizations and mortality demonstrated increases during December through February. The results of this study demonstrate age-specific seasonal variations in the clinical expression of asthma. Perhaps the treatment and prevention of asthma hospitalizations and mortality might be improved through further understanding of these trends.
THE SURGICAL TREATMENT OF CONICAL CORNEA.
Authors: ROBERT SATTLER
Journal: JAMA (1900)

Surgery in the treatment of conical cornea has a limited application. The various surgical measures which have from time to time been advised and practiced are justifiable only in certain progressive or confirmed expressions of this congenital deformity of the eye. In the main, the purpose of surgical intervention concerns itself with attempts: 1. To arrest an inexorable advance of a deformed central area of the cornea by converting this region—in part or altogether—into an opaque scar or a series of cicatricial lines, thereby affording a more or less effectual check to an otherwise hopeless progression. 2. To effect a betterment of vision in confirmed cases which have been rendered helpless in consequence of hopelessly reduced sight, after all other methods of treatment, including every kind and combination of lenses, stenopaic appliances, etc., have been discarded as useless. <h3>ARREST OF ADVANCING DEFORMITY.</h3> In taking up the first proposition, it must
Abstract 4310: Prospective isolation of clongenic mantle cell lymphoma initiating cells
Authors: Zheng Chen, Paul Ayala, Michael Wang, Luis Fayad, Ruth L. Katz, Jorge Romaguera, Nancy Caraway, Sattva S. Neelapu, Larry W. Kwak, Paul Simmons, McCarty Nami
Journal: Cancer Research (2010)

Abstract We have prospectively isolated and characterized clonogenic cells with self-renewal capacities from mantle cell lymphoma (MCL), a particularly deadly form of non-hodgkin's lymphoma (NHL). Self-renewal and tumorigenic activities were enriched in MCL cell fractions that lacked expression of the prototypic B cell surface marker, CD19. CD45+CD19- cells represented a relatively small fraction of the total MCL tumor cells, however, they recapitulated the heterogeneity of original patient tumors upon transplantation into immunodeficient mice. As few as 100 of these cells displayed self-renewal capacities in secondary and tertiary recipient mice by in vivo limiting dilution assays. Similar to leukemic stem cells, CD45+CD19- MCL cells also displayed a quiescent status as determined by dye efflux assays. In summary, this study is the first to isolate subpopulations of MCL cells that have self-renewal and tumorigenic capacities. Identification and characterization of MCL-ICs is an important first step toward understanding how self-renewal and tumorigenicity are regulated in MCL. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4310.
117. HSPG Binding Properties of Adeno- Associated Virus Retargeting Mutants and Consequences for Their In Vivo Tropism
Authors: Daniela Goldnau, Luca Perabo, Kathryn White, Jan Endell, Sibille Humme, Lorraine Work, Hanna Jannicki, Michael Hallek, Andrew H. Baker, Hildegard Buening
Journal: Molecular Therapy (2006)

Different technologies have been developed to control or redirect tropism of adeno-associated virus of type 2 (AAV-2) by genetic capsid modification. Many of these approaches are based on the introduction of peptide sequences on the viral capsid in order to provide the vector with the ability to bind particular cellular receptors. To obtain selective vectors however, simultaneous abrogation of capsid usage of natural receptors is essential. Insertions at amino acid position 587 of the major capsid protein VP1 ablated the heparan sulphate proteoglycan binding of wild-type AAV in some, but not all previously described AAV targeting vectors.
450 SERUM MARKERS OF LIVER FIBROSIS IDENTIFY PATIENTS WITH MILD AND SEVERE HEPATITIS C RECURRENCE DURING THE FIRST MONTHS AFTER LIVER TRANSPLANTATION
Authors: J.A. Carrión, G. Fernandez-Varo, M. Bruguera, J.-C. García-Valdecasas, X. Forns, W. Jiménez, M. Navasa
Journal: Journal of Hepatology (2009)
Priority in Craniotomy and Microcephalus.
Authors: William Fuller
Journal: JAMA (1894)

Grand Rapids, Mich., Nov. 5, 1894. <h3>To the Editor:</h3> —I desire to state through theJournal, that craniotomy for microcephalus is as distinctly American as ovariotomy and several other operations instituted in this country for the benefit of humanity. I take issue with Prof. Carl Beck in his paper published in theJournalOctober 27, and November 3, on two points: 1, in his statement that Lannelongue of Paris, is<i>the pioneer</i>, if I understand the meaning of this word aright to be the man who moves in first. This point, however, does not afflict me since in point of time the date of my operation obliged him to place me first upon the list of operators. I reported two cases in the same paper dated 1878, which was widely circulated in several countries and severely commented upon by both the medical and secular press. I have operated altogether five